AAP Issues Caution on Leucovorin for Autism Amid Growing Demand

The American Academy of Pediatrics (AAP) has announced that leucovorin, a form of vitamin B9, should not be routinely used in children with autism, citing a lack of supporting evidence regarding its benefits and risks. This announcement comes as parents express heightened interest following federal discussions on autism treatments.

The interest in leucovorin surged after it was mentioned in a White House press conference. The drug, initially developed by GSK for chemotherapy patients, is being eyed for use beyond its original purpose. While the FDA considers its approval for cerebral folate deficiency, links to autism treatment remain unsupported by extensive research.

Dr. Kristin Sohl of the University of Missouri emphasized the need for cautious use. Though the drug holds promise, many uncertainties exist, including its target population and appropriate dosing. The AAP stresses the importance of shared decision-making and close monitoring for adverse effects if prescribed for autism.